The global equine health market is likely to derive growth from the increasing number of product launches, aimed at enhancing equine health. According to a report by Fortune Business Insights, titled “Equine Health Market Size, Share & Industry Analysis, By Product Type (Drugs, Vaccines, Feed additives), By Disease Type (Nile virus, Potomac horse fever, Equine rabies, Tetanus, Equine influenza, Others), By Distribution Channel (Veterinary hospitals & clinics, Retail pharmacy, Online pharmacies) and Regional Forecast, 2019-2026,” the market will benefit from the increasing prevalence of infectious animal diseases.
High Prevalence of Equine Diseases to Boost the Market in North America
Besides the factors mentioned above, the report classifies the market on the basis of regional demographics. The report categorizes the global equine health market into five main regions that are North America, Latin America, the Middle East and Africa, Asia Pacific, and Europe. Among these regions, the rate of adoption of equine as a pet is the highest in North America. Moreover, there is a high prevalence of infectious diseases in this region. Along with the aforementioned factors, the availability of excellent treatment options will aid the growth of the equine health market in North America. Increased healthcare expenditure is another factor that has contributed to market growth.
Some of the leading companies that are operating in the global equine health market are:
Top players in the global Type 1 Equine Health Market include:
- Boehringer Ingelheim International GmbH
- Bayer AG
- Elanco, Intervet Inc.
- Purina Animal Nutrition LLC
- Equine Products UK LTD
- Vetoquinol S.A.
More Trending Topics From Fortune Business [email protected]